Potential conflict of interest: Dr. Rockey consults for Ono and received grants from Hyperion and Actelion. Dr. Vierling advises Idenix-Novartis, Ikaria, Intercept, Merck, Mochida, Novartis, Ocera, Pfizer, Pharmasset, Roche, Sundise, Vertex, and Zymogenetics. Dr. Mantry is on the speakers' bureau for Salix and received grants from Hyperion. Dr. McCashland is on the speakers' bureau for Salix and Vertex. Dr. K.R. Reddy consults for and received grants from Merck, Gilead, Genentech-Roche, Janssen, Vertex, Idenix, and Bristol-Myers Squibb. Dr. K.G. Reddy received grants from Hyperion. Dr. Bass consults for and advises Hyperion. Dr. Dickinson owns stock in Hyperion. Dr. Norris owns stock in Hyperion. Dr. Coakley owns stock in Hyperion. Dr. Mokhtarani owns stock in Hyperion. Dr. Scharschmidt owns stock in Hyperion.
Liver Failure/Cirrhosis/Portal Hypertension
Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy
Article first published online: 25 FEB 2014
© 2014 The Authors. Hepatology published by Wiley on behalf of the American Association for the Study of Liver Diseases.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Volume 59, Issue 3, pages 1073–1083, March 2014
How to Cite
Rockey, D. C., Vierling, J. M., Mantry, P., Ghabril, M., Brown, R. S., Alexeeva, O., Zupanets, I. A., Grinevich, V., Baranovsky, A., Dudar, L., Fadieienko, G., Kharchenko, N., Klaryts'ka, I., Morozov, V., Grewal, P., McCashland, T., Reddy, K. G., Reddy, K. R., Syplyviy, V., Bass, N. M., Dickinson, K., Norris, C., Coakley, D., Mokhtarani, M., Scharschmidt, B. F. and for the HALT-HE Study Group (2014), Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. Hepatology, 59: 1073–1083. doi: 10.1002/hep.26611
The study was funded by Hyperion Therapeutics, Inc.
- Issue published online: 25 FEB 2014
- Article first published online: 25 FEB 2014
- Accepted manuscript online: 11 JUL 2013 07:50AM EST
- Manuscript Accepted: 22 JUN 2013
- Manuscript Received: 3 APR 2013
Additional Supporting Information may be found in the online version of this article.
|hep26611-sup-0001-supptable.docx||27K||Supplemental table for on-line publication: Subject Discontinuations in Relation to Treatment Arms|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.